ClinicalTrials.gg
CompletedNCT01095835Updated Nov 3, 2016Results posted

A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

A Phase 3 interventional study of Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg and Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg in Hepatitis B, Chronic, sponsored by Hoffmann-La Roche. Completed at 22 sites in Italy. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-11-03.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
131
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic — 1 open to participants now, 1 under way, none of them phase 3. peginterferon alfa-2a · Hepatitis B, Chronic.

Enrollment
26th of 59
131 · median 114
Started
2005
with 4 others
Phase 3
11 of 59
none open now
Registered
21st of 59
by date
Lead sponsor
22 of 59
Hoffmann-La Roche

Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, this one is the 26th largest by enrollment, is one of 5 that started in 2005, is one of 11 in phase 3, and was the 21st registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

1 of the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

This study will compare the efficacy and safety of 2 different durations of treatment with pegylated interferon (PEG-IFN) alfa-2a in participants with Hepatitis B e Antigen (HBeAg)-negative chronic hepatitis B virus (HBV). It will also compare PEG-IFN alfa 2a treatment alone and in combination with lamivudine (LAM). The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adults 18-70 years of age;
  • HBeAg-negative chronic for >/=6 months;
  • liver disease consistent with chronic hepatitis B.

Exclusion criteria

Exclusion Criteria:

  • interferon-based, systemic anti-, antiviral, anti-neoplastic, or immunomodulatory therapy \</=12 months before first dose of study drug;
  • non-responders to previous interferon therapy;
  • co-infection with hepatitis A, C or D, or with (HIV);
  • hepatocellular cancer;
  • compensated (Child A, score 6) or decompensated liver disease (Child B or C).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    PEG-IFN48

    Treatment with PEG-IFN in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks.

    Drug: Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg

  • Experimental
    PEG-IFN96

    Treatment with PEG-IFN in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks followed by another 48 weeks of PEG-IFN treatment (total 96 weeks of treatment).

    Drug: Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg · Drug: Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg

  • Experimental
    PEG-IFN+LAM96

    Treatment with PEG-IFN and lamivudine in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks followed by 48 weeks of only PEG-IFN treatment (total 96 weeks of treatment).

    Drug: Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg · Drug: Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg · Drug: Lamivudine (LAM)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving the Combined Response at the End of the Follow-up Period

    Combined response was defined as alanine aminotransferase (ALT) normalization plus lowering of hepatitis B virus (HBV) deoxyribo nucleic acid (DNA) levels to \<20,000 copies/mL (\<3,400 IU/mL) and was measured at the end of the 48-week follow-up period. Participants with missing 48 weeks follow-up measurements were considered as non-responders. However, if the scheduled 48-weeks post-treatment tests were performed earlier or later than 48 weeks post-treatment, but not earlier than 36 weeks post-treatment, the corresponding results were considered to determine response.

    Time frame: At the end of the 48-week follow-up period at Week 144

Secondary outcomes

  1. Percentage of Participants Achieving the Combined Response at the End of Treatment

    Combined response was defined as ALT normalization plus lowering of HBV-DNA levels to \<20,000 copies/mL (\<3,400 IU/mL). In case of missing end of treatment measurements, the next available post-treatment value was used.

    Time frame: At end of treatment at Week 48 or 96 depending on the study arm

  2. Percentage of Participants Achieving the Combined Response at 24 Weeks of Follow-up

    Combined response was defined as ALT normalization plus lowering of HBV-DNA levels to \<20,000 copies/mL (\<3,400 IU/mL). In case of missing week-24 post-treatment measurements, the nearest value with respect to the schedule time point in the time window 12 weeks post treatment until study end was used.

    Time frame: At the end of 24 weeks of follow-up at Week 120

  3. Percentage of Participants Achieving Combined Response Using a Cut-Off for HBV-DNA Levels to 2,000 IU/mL

    Combined response was defined here as ALT normalization plus lowering HBV-DNA levels to a cutt-off \<2,000 IU/mL. In case of missing end of treatment measurements, the next available post-treatment value was used. In case of missing week-24 post-treatment measurements, the nearest value with respect to the schedule time point in the time window 12 weeks post treatment until study end was used. Participants with missing 48 weeks follow-up measurements were considered as non-responders. However, if the scheduled 48-weeks post-treatment tests were performed earlier or later than 48 weeks post-treatment, but not earlier than 36 weeks post-treatment, the corresponding results were considered to determine response.

    Time frame: At end of treatment at Week 48 or 96 depending on the study arm, at the end of 24 weeks of follow-up at Week 120 and at the end of the follow-up period at Week 144

  4. Percentage of Participants Achieving Histological Response

    Histological response was defined as an improvement by \>/= 2 in the Necroinflammatory Grading and/or by an improvement by \>/= 1 score in Fibrosis Staging according to Ishak. Necroinflammatory Grading ranges 0-14 and is the combined score for necrosis, range 0-10 and inflammation, range 0-4. The participant is scored for only one inflammatory condition. A higher score indicates worse condition. Fibrosis Staging according to Ishak ranges 0-6 and a higher score indicates greater fibrosis.

    Time frame: At the end of the 48-week follow-up period at Week 144

  5. Change From Baseline of Quantitative Hepatitis B Surface Antigen (HbsAg) Level at the End of Treatment

    Time frame: At the end of treatment at Week 48 or 96 depending on the study arm

  6. Percentage of Participants With Lamivudine Genotype Resistance During PEG-IFN+LAM96 Combined Therapy

    Lamivudine resistance mutations were assessed by detection of the following mutations: rtL80V, rtL80I, rtV173G, rtV173L, rtL180M, rtA181T, rtA181V, rtM204V, rtM204I and rtN236T.

    Time frame: At the end of the treatment period at Week 96

Other outcomes

  1. Percentage of Participants With ALT Normalization

    Time frame: At end of treatment at Week 48 or 96 depending on the study arm, at the end of 24 weeks of follow-up at Week 120 and at the end of the follow-up period at Week 144

  2. Percentage of Participants With HBV-DNA Lowering to <3,400 IU/mL and to < 2,000 IU/mL

    Time frame: At end of treatment at Week 48 or 96 depending on the study arm, at the end of 24 weeks of follow-up at Week 120 and at the end of the follow-up period at Week 144

  3. Percentage of Participants With HBV-DNA Below Limit of Quantification

    HBV-DNA limit \< 6 IU/mL was defined as below quantification.

    Time frame: At end of treatment at Week 48 or 96 depending on the study arm, at the end of 24 weeks of follow-up at Week 120 and at the end of the follow-up period at Week 144

  4. Percentage of Participants With Loss of Hepatitis B Surface Antigen (HbsAg) and Hepatitis B Surface Antibodies (Anti-HBs) Seroconversion

    This outcome measure presents percentage of participants with a combined response of HBsAg \< 5 IU/mL and anti-HBs positive. Positive anti-HBs represents antibodies produced against Hepatitis B Surface Antigen (HBsAg) and is an indication of recovery and immunity from HBV infection.

    Time frame: At end of treatment at Week 48 or 96 depending on the study arm, at the end of 24 weeks of follow-up at Week 120 and at the end of the follow-up period at Week 144

07

Results

Posted Nov 3, 2016

Participant flow

Participant flow — Overall Study
MilestonePEG-IFN48PEG-IFN96PEG-IFN+LAM96
Started515225
Completed414017
Not completed10128
Withdrew: Adverse event866
Withdrew: Lack of efficacy010
Withdrew: Physician decision001
Withdrew: Withdrawal by subject130
Withdrew: Non study compliance001
Withdrew: Protocol violation120

Outcome measures

PrimaryPercentage of Participants Achieving the Combined Response at the End of the Follow-up Period

Combined response was defined as alanine aminotransferase (ALT) normalization plus lowering of hepatitis B virus (HBV) deoxyribo nucleic acid (DNA) levels to \<20,000 copies/mL (\<3,400 IU/mL) and was measured at the end of the 48-week follow-up period. Participants with missing 48 weeks follow-up measurements were considered as non-responders. However, if the scheduled 48-weeks post-treatment tests were performed earlier or later than 48 weeks post-treatment, but not earlier than 36 weeks post-treatment, the corresponding results were considered to determine response.

Time frame:
At the end of the 48-week follow-up period at Week 144
Reported as:
Number · percentage of participants
Percentage of Participants Achieving the Combined Response at the End of the Follow-up Period
percentage of participantsPEG-IFN48PEG-IFN96PEG-IFN+LAM96
Percentage of Participants Achieving the Combined Response at the End of the Follow-up Period11.825.020.0
Statistical analysis
  • PEG-IFN48 vs PEG-IFN96 · Chi-squared · p = 0.08
SecondaryPercentage of Participants Achieving the Combined Response at the End of Treatment

Combined response was defined as ALT normalization plus lowering of HBV-DNA levels to \<20,000 copies/mL (\<3,400 IU/mL). In case of missing end of treatment measurements, the next available post-treatment value was used.

Time frame:
At end of treatment at Week 48 or 96 depending on the study arm
Reported as:
Number · percentage of participants
Percentage of Participants Achieving the Combined Response at the End of Treatment
percentage of participantsPEG-IFN48PEG-IFN96PEG-IFN+LAM96
Percentage of Participants Achieving the Combined Response at the End of Treatment29.438.532.0
SecondaryPercentage of Participants Achieving the Combined Response at 24 Weeks of Follow-up

Combined response was defined as ALT normalization plus lowering of HBV-DNA levels to \<20,000 copies/mL (\<3,400 IU/mL). In case of missing week-24 post-treatment measurements, the nearest value with respect to the schedule time point in the time window 12 weeks post treatment until study end was used.

Time frame:
At the end of 24 weeks of follow-up at Week 120
Reported as:
Number · percentage of participants
Percentage of Participants Achieving the Combined Response at 24 Weeks of Follow-up
percentage of participantsPEG-IFN48PEG-IFN96PEG-IFN+LAM96
Percentage of Participants Achieving the Combined Response at 24 Weeks of Follow-up23.528.824.0
SecondaryPercentage of Participants Achieving Combined Response Using a Cut-Off for HBV-DNA Levels to 2,000 IU/mL

Combined response was defined here as ALT normalization plus lowering HBV-DNA levels to a cutt-off \<2,000 IU/mL. In case of missing end of treatment measurements, the next available post-treatment value was used. In case of missing week-24 post-treatment measurements, the nearest value with respect to the schedule time point in the time window 12 weeks post treatment until study end was used. Participants with missing 48 weeks follow-up measurements were considered as non-responders. However, if the scheduled 48-weeks post-treatment tests were performed earlier or later than 48 weeks post-treatment, but not earlier than 36 weeks post-treatment, the corresponding results were considered to determine response.

Time frame:
At end of treatment at Week 48 or 96 depending on the study arm, at the end of 24 weeks of follow-up at Week 120 and at the end of the follow-up period at Week 144
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Combined Response Using a Cut-Off for HBV-DNA Levels to 2,000 IU/mL
percentage of participantsPEG-IFN48PEG-IFN96PEG-IFN+LAM96
End of treatment29.438.528.0
24 weeks of follow-up21.626.920.0
48 weeks of follow-up11.823.120.0
SecondaryPercentage of Participants Achieving Histological Response

Histological response was defined as an improvement by \>/= 2 in the Necroinflammatory Grading and/or by an improvement by \>/= 1 score in Fibrosis Staging according to Ishak. Necroinflammatory Grading ranges 0-14 and is the combined score for necrosis, range 0-10 and inflammation, range 0-4. The participant is scored for only one inflammatory condition. A higher score indicates worse condition. Fibrosis Staging according to Ishak ranges 0-6 and a higher score indicates greater fibrosis.

Time frame:
At the end of the 48-week follow-up period at Week 144
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Histological Response
percentage of participantsPEG-IFN48PEG-IFN96PEG-IFN+LAM96
Percentage of Participants Achieving Histological Response13.75.88.0
SecondaryChange From Baseline of Quantitative Hepatitis B Surface Antigen (HbsAg) Level at the End of Treatment
Time frame:
At the end of treatment at Week 48 or 96 depending on the study arm
Reported as:
Mean · IU/mL
Change From Baseline of Quantitative Hepatitis B Surface Antigen (HbsAg) Level at the End of Treatment
IU/mLPEG-IFN48PEG-IFN96PEG-IFN+LAM96
Baseline (n=51, 51, 25)9642.6 ± 19756.47229.8 ± 6459.08981.0 ± 7728.5
Change from baseline (n=44, 44, 20)-2801.1 ± 14691.2-2282.1 ± 6007.1-3121.2 ± 7128.9
SecondaryPercentage of Participants With Lamivudine Genotype Resistance During PEG-IFN+LAM96 Combined Therapy

Lamivudine resistance mutations were assessed by detection of the following mutations: rtL80V, rtL80I, rtV173G, rtV173L, rtL180M, rtA181T, rtA181V, rtM204V, rtM204I and rtN236T.

Time frame:
At the end of the treatment period at Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Lamivudine Genotype Resistance During PEG-IFN+LAM96 Combined Therapy
percentage of participantsPEG-IFN+LAM96
Percentage of Participants With Lamivudine Genotype Resistance During PEG-IFN+LAM96 Combined Therapy0
Other pre-specifiedPercentage of Participants With ALT Normalization
Time frame:
At end of treatment at Week 48 or 96 depending on the study arm, at the end of 24 weeks of follow-up at Week 120 and at the end of the follow-up period at Week 144
Reported as:
Number · percentage of participants
Percentage of Participants With ALT Normalization
percentage of participantsPEG-IFN48PEG-IFN96PEG-IFN+LAM96
End of treatment35.340.440.0
24 weeks of follow-up45.146.240.0
48 weeks of follow-up35.334.636.0
Other pre-specifiedPercentage of Participants With HBV-DNA Lowering to <3,400 IU/mL and to < 2,000 IU/mL
Time frame:
At end of treatment at Week 48 or 96 depending on the study arm, at the end of 24 weeks of follow-up at Week 120 and at the end of the follow-up period at Week 144
Reported as:
Number · percentage of participants
Percentage of Participants With HBV-DNA Lowering to <3,400 IU/mL and to < 2,000 IU/mL
percentage of participantsPEG-IFN48PEG-IFN96PEG-IFN+LAM96
End of treatment: HBV-DNA < 3,400 IU/mL60.867.376.0
24 weeks of follow-up: HBV-DNA < 3,400 IU/mL23.530.824.0
48 weeks of follow-up: HBV-DNA < 3,400 IU/mL11.830.820.0
End of treatment: HBV-DNA < 2,000 IU/mL58.867.372.0
24 weeks of follow-up: HBV-DNA < 2,000 IU/mL21.628.820.0
48 weeks of follow-up: HBV-DNA < 2,000 IU/mL11.828.820.0
Other pre-specifiedPercentage of Participants With HBV-DNA Below Limit of Quantification

HBV-DNA limit \< 6 IU/mL was defined as below quantification.

Time frame:
At end of treatment at Week 48 or 96 depending on the study arm, at the end of 24 weeks of follow-up at Week 120 and at the end of the follow-up period at Week 144
Reported as:
Number · percentage of participants
Percentage of Participants With HBV-DNA Below Limit of Quantification
percentage of participantsPEG-IFN48PEG-IFN96PEG-IFN+LAM96
End of treatment17.630.824.0
24 weeks of follow-up0.07.74.0
48 weeks of follow-up2.07.78.0
Other pre-specifiedPercentage of Participants With Loss of Hepatitis B Surface Antigen (HbsAg) and Hepatitis B Surface Antibodies (Anti-HBs) Seroconversion

This outcome measure presents percentage of participants with a combined response of HBsAg \< 5 IU/mL and anti-HBs positive. Positive anti-HBs represents antibodies produced against Hepatitis B Surface Antigen (HBsAg) and is an indication of recovery and immunity from HBV infection.

Time frame:
At end of treatment at Week 48 or 96 depending on the study arm, at the end of 24 weeks of follow-up at Week 120 and at the end of the follow-up period at Week 144
Reported as:
Number · percentage of participants
Percentage of Participants With Loss of Hepatitis B Surface Antigen (HbsAg) and Hepatitis B Surface Antibodies (Anti-HBs) Seroconversion
percentage of participantsPEG-IFN48PEG-IFN96PEG-IFN+LAM96
End of treatment2.03.80.0
24 weeks of follow-up0.05.80.0
48 weeks of follow-up0.07.70.0

Adverse events

Collected over Up to 48 weeks after last study treatment dose (up to Week 144). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PEG-IFN48—7/50 (14%)25/50 (50%)
PEG-IFN96—3/52 (5.8%)27/52 (51.9%)
PEG-IFN + LAM96—6/25 (24%)13/25 (52%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventPEG-IFN48PEG-IFN96PEG-IFN + LAM96
Infected cystInfections and infestations0/500/521/25
Guillain-Barre syndromeNervous system disorders0/500/521/25
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/500/521/25
Muscular weaknessMusculoskeletal and connective tissue disorders0/500/521/25
Meniscus lesionInjury, poisoning and procedural complications0/500/521/25
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/500/521/25
Hypertensive crisisVascular disorders0/500/521/25
Iron deficiency anaemiaBlood and lymphatic system disorders1/500/520/25
DiarrhoeaGastrointestinal disorders1/500/520/25
PyrexiaGeneral disorders1/500/520/25
Most frequent other events
Showing 10 of 36
Most frequent other events
EventPEG-IFN48PEG-IFN96PEG-IFN + LAM96
AstheniaGeneral disorders17/5019/5211/25
PyrexiaGeneral disorders18/5019/528/25
HeadacheNervous system disorders13/508/527/25
NeutropeniaBlood and lymphatic system disorders12/509/523/25
Influenza like illnessGeneral disorders9/5010/524/25
MyalgiaMusculoskeletal and connective tissue disorders7/508/524/25
ThrombocytopeniaBlood and lymphatic system disorders6/506/521/25
Abdominal painGastrointestinal disorders4/504/523/25
ArthralgiaMusculoskeletal and connective tissue disorders6/506/523/25
PruritusSkin and subcutaneous tissue disorders5/506/523/25

Baseline characteristics

The ITT population included all participants randomized who received at least one dose of study medication.

Age, Continuous
Age, Continuous(years)PEG-IFN48PEG-IFN96PEG-IFN+LAM96Total
Mean45.1 ± 10.244.1 ± 10.445.6 ± 8.644.6 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)PEG-IFN48PEG-IFN96PEG-IFN+LAM96Total
Female187732
Male33451896
08

Study locations

22 sites
  • Caserta, Campania 81100, Italy
  • Napoli, Campania 80131, Italy
  • Napoli, Campania 80135, Italy
  • Bologna, Emilia-Romagna 40138, Italy
  • Parma, Emilia-Romagna 43100, Italy
  • Reggio Emilia, Emilia-Romagna 42100, Italy
  • Trieste, Friuli-Venezia Giulia 34100, Italy
  • Udine, Friuli-Venezia Giulia 33100, Italy
  • Brescia, Lombardia 25125, Italy
  • Milano, Lombardia 20121, Italy
  • Milano, Lombardia 20122, Italy
  • Torino, Piemonte 10126, Italy
  • Torino, Piemonte 10149, Italy
  • Bari, Puglia 70124, Italy
  • Castellana Grotte, Puglia 70013, Italy
  • San Giovanni Rotondo, Puglia 71013, Italy
  • Cagliari, Sardegna 09042, Italy
  • Messina, Sicilia 98124, Italy
  • Palermo, Sicilia 90127, Italy
  • Pisa, Toscana 56124, Italy
  • Padova, Veneto 35128, Italy
  • Verona, Veneto 37134, Italy
09

References and documents

Publications

  • Lampertico P, Vigano M, Di Costanzo GG, Sagnelli E, Fasano M, Di Marco V, Boninsegna S, Farci P, Fargion S, Giuberti T, Iannacone C, Regep L, Massetto B, Facchetti F, Colombo M; PegBeLiver Study Group. Randomised study comparing 48 and 96 weeks peginterferon alpha-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut. 2013 Feb;62(2):290-8. doi: 10.1136/gutjnl-2011-301430. Epub 2012 Aug 2. PubMed 22859496 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2005, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 6 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2010
First posted
Mar 30, 2010
Start
Feb 2005
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Results first posted
Nov 3, 2016
Last update
Nov 3, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01095835
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 30, 2010
Start date
Feb 2005
Primary completion
Jan 2010
Completion
Jan 2010
Results posted
Nov 3, 2016
Last update
Nov 3, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2a

Start the discussion